Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.

Authors

AeRang Kim, George Washington University
Brigitte C Widemann
Mark Krailo
Nalini Jayaprakash
Elizabeth Fox
Brenda WeigelFollow
Susan M Blaney

Document Type

Journal Article

Publication Date

9-1-2015

Journal

Pediatric Blood and Cancer

Volume

62

Issue

9

Inclusive Pages

1562-1566

DOI

10.1002/pbc.25548

Keywords

Angiogenesis Inhibitors--therapeutic use; Antineoplastic Agents--therapeutic use; Kidney Neoplasms--drug therapy; Niacinamide--analogs & derivatives; Phenylurea Compounds--therapeutic use; Protein Kinase Inhibitors--therapeutic use; Rhabdomyosarcoma--drug therapy; Salvage Therapy; Wilms Tumor--drug therapy

APA Citation

Kim, A., Widemann, B. C., Krailo, M., Jayaprakash, N., Fox, E., Weigel, B., & Blaney, S. M. (2015). Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the children's oncology group. Pediatric Blood and Cancer, 62(9), 1562-1566.

Peer Reviewed

1